Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8790158 | Urologic Oncology: Seminars and Original Investigations | 2018 | 7 Pages |
Abstract
Our data suggest that patients who did not receive NAC benefit from an adequate LND. However, the receipt of an adequate LND was not associated with an OS benefit in patients pretreated with NAC. Our study indicates that the receipt of NAC may eradicate micrometastatic disease, and thus limit the benefit of an adequate LND.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Nicolas M.D., Jacqueline M. M.D., Alexander P. M.D., Thomas M.D., Stuart R. Sc.D., Philipp M.D., Mani M.D., Adam S. M.D., Florian M.D., Joachim M.D., Maxine M.P.H., Ph.D., Quoc-Dien M.D.,